IP Library Granted Patent US 7,754,678
Granted Patent B2
US 7,754,678 · App. 11/251,734 · Granted Jul 13, 2010

Membrane penetrating peptides and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,678
App. No.
11/251,734
Granted
Jul 13, 2010
Kind
B2
Abstract

The present invention is directed to membrane penetrating peptides useful as in vivo, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Claims (12)

1. A fusion protein for delivery of an organic molecule into a cell comprising a membrane penetrating peptide attached to said organic molecule, wherein the membrane penetrating peptide is not full length human Period 1 protein or full length human Period 3 protein, said membrane penetrating peptide comprising a peptide selected from the group consisting of the peptides: RRHHCRSKAKRSRHH (SEQ ID NO:56), SRRHHCRSKAKRSRHH (SEQ ID NO: 16), SARHHCRSKAKRSRHH (SEQ ID NO:40), SRAHHCRSKAKRSRHH (SEQ ID NO:41), SRRAHCRSKAKRSRHH (SEQ ID NO:42), SRRHACRSKAKRSRHH (SEQ ID NO:43), SRRHHARSKAKRSRHH (SEQ ID NO:44), SRRHHCRAKAKRSRHH (SEQ ID NO:46), SRRHHCRSAAKRSRHH (SEQ ID NO:47), SRRHHCRSKAARSRHH (SEQ ID NO:48), SRRHHCRSKAKASRHH (SEQ ID NO:49), SRRHHCRSKAKRARHH (SEQ ID NO:50), SRRHHCRSKAKRSAHH (SEQ ID NO:51) and RRHHCRSKAKRSR (SEQ ID NO:52) and RKGKHKRKKLP (SEQ ID NO:55).

2. The fusion protein according to claim 1 , wherein the membrane penetrating peptide comprises the peptide GRKGKHKRKKLP (SEQ ID NO: 27).

3. The fusion protein according to claim 2 , wherein the membrane penetrating peptide comprises a peptide selected from the group consisting of the peptides: SRRHHCRSKAKRSRHH (SEQ ID NO: 16) and GRRHHCRSKAKRSRHH (SEQ ID NO: 17).

4. The fusion protein of claim 1 , wherein the organic molecule is directly chemically attached to the membrane penetrating peptide or by a linker.

5. The fusion protein of claim 4 , wherein the linker is an amino acid linker or a polypeptide linker.

6. The fusion protein of claim 1 , wherein the membrane penetrating protein is produced by recombinant technology, chemical synthesis or degradation of a precursor protein.

7. The fusion protein of claim 1 , wherein the organic molecule is a small organic molecule, peptide, protein, lipoprotein, glycoprotein, polysaccharide, oligonucleotide, or antisense oligonucleotide.

8. A fusion protein for delivery of a peptide, protein or glycoprotein into a cell consisting essentially of a membrane penetrating peptide attached to said peptide, protein or glycoprotein, wherein said membrane penetrating peptide comprises a peptide that is selected from the group consisting of human Period 1 nuclear localization sequence RRHHCRSKAKRSRHH (SEQ ID NO:56) and human Period 3 nuclear localization sequence RKGKHKRKKLP (SEQ ID NO:55) wherein the membrane penetrating peptide is not full length human Period 1 protein or full length human Period 3 protein.

9. A fusion protein for delivery of an oligonucleotide into a cell comprising a membrane penetrating peptide attached to said oligonucleotide, wherein said membrane penetrating peptide is selected from the group consisting of the peptides: RRHHCRSKAKRSRHH (SEQ ID NO:56) and RKGKHKRKKILP (SEQ ID NO:55).

10. The fusion protein of claim 5 , wherein the linker is a polypeptide linker of five or fewer amino acids.

11. The fusion protein of claim 5 , wherein the polypeptide linker is selected from the group consisting of GFLG (SEQ ID NO: 13), GG, GL and G.

12. A purified fusion protein for delivery of a peptide, protein or glycoprotein into a cell comprising a membrane penetrating peptide, said membrane penetrating peptide including a nuclear localization sequence, said membrane penetrating peptide being attached to said peptide, protein or glycoprotein, wherein said nuclear localization sequence of said membrane penetrating peptide comprises a peptide that is selected from the group consisting of human Period 1 nuclear localization sequence RRHHCRSKAKRSRHH (SEQ ID NO:56) and human Period 3 nuclear localization sequence RKGKHKRKKLP (SEQ ID NO:55) wherein the membrane penetrating peptide is not full length human Period 1 protein or full length human Period 3 protein.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNOR AND THE NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 034566 FRAME 0938. ASSIGNOR(S) HEREBY CONFIRMS THE THE CORRECT NAME OF THE ASSIGNEE SHOULD BE AVENTIS HOLDINGS INC. AND THE CORRECT NAME OF THE ASSIGNEE SHOULD BE AVENTISUB INC.. Recorded Feb 3, 2015
From: AVENTIS HOLDINGS INC.
To: AVENTISUB INC.
Reel/Frame 034891/0063 →
CHANGE OF NAME Recorded Feb 3, 2015
From: AVENTISUB INC.
To: AVENTISUB LLC
Reel/Frame 034891/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: HMR PHARMA INC.
To: AVENTIS HOLDINGS INC.
Reel/Frame 034443/0158 →
BILL OF SALE Recorded Dec 9, 2014
From: AVENTIS HOLDINGS INC.
To: AVENTISUB II INC.
Reel/Frame 034566/0868 →
MERGER Recorded Dec 9, 2014
From: AVENTISUB II INC.
To: AVENTIS HOLDINGS INC.
Reel/Frame 034566/0931 →
MERGER Recorded Dec 9, 2014
From: AVENTISUB INC.
To: AVENTISUB II INC.
Reel/Frame 034566/0938 →
MERGER Recorded Dec 9, 2014
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTISUB LLC
Reel/Frame 034566/0958 →
MERGER Recorded Dec 9, 2014
From: AVENTIS PHARMACEUTICALS INC.
To: HMR PHARMA INC.
Reel/Frame 034442/0880 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: AVENTIS PHARMACEUTICALS INC.
To: HMR PHARMA INC.
Reel/Frame 034443/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2010
From: GUO, YONG; YAO, ZHENGBIN; MORSE, CLARENCE C.; KEESLER, GEORGE A., JR.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 024092/0622 →